Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemigliptin + dapagliflozin
- Development stage
- Phase 1
- Lead developer
- LG Chem
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gemigliptin + dapagliflozin is a fixed-dose combination of two oral antidiabetic agents used for the management of type 2 diabetes mellitus. Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner[3][5]. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by inhibiting renal glucose reabsorption, leading to increased urinary glucose excretion[1][6]. The combination targets complementary mechanisms to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on diet, exercise, or other antidiabetic medications. This fixed-dose product has been developed and marketed primarily by LG Chem[4].
- Brand names
- Zemidapa
- Other names
- gemigliptin + dapagliflozingemigliptin/dapagliflozin fixed-dose combination
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on gemigliptin + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemigliptin + dapagliflozin.